Elanco Animal Health (ELAN) said Monday it has sold certain future tiered royalties and commercial milestones of its lotilaner ophthalmic solution Xdemvy 0.25% to funds affiliated with Blackstone's (BX) Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash.
The company said it will use the proceeds to pay down debt.
Elanco said the deal applies to certain tiered royalties linked to the US net sales of Xdemvy from April 2025 to August 2033 as well as certain commercial milestones.
The company said it continues to hold the rights to all royalty payments on net sales outside US and on any future applications of lotilaner beyond ophthalmic solutions.
Elanco's stock rose 2% in recent Monday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。